Stocks-VRTX-Vertex Pharmaceuticals Incorporated

VRTX Vertex Pharmaceuticals Incorporated

349.53 -4.75 (-1.34%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

Vertex Pharmaceuticals Incorporated price

-0.19% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
90.21B
Day’s Range
347.90
-
354.47
52W Range
276.16
-
366.16
Volume (3M)
1.02M
Price-Earnings Ratio
27.02
Revenue
9.36B
Pinned Post
Genome Engineering
AstraZeneca's Alexion completes purchase and licence agreement from Pfizer 👉 Alexion, $AZN.L (AstraZeneca) Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from $PFE (Pfizer) . 👉... Show More
Like CommentShare
null
.
Top Discussions
Alexandru Pop
United Kingdom
PORTFOLIO UPDATE Stocks on Tuesday ended in negative territory, though well off their session lows. The central bank's monetary policy committee will end its two-day meeting tomorrow. The spotlight was garnered by Instacart's market debut, following on the heels of $ARM (ARM Holdings PLC)... Show More
Like CommentShare
null
.
Sebastian Kubica
Edited
📈 Hey copiers and followers! I've been deeply analyzing two intriguing stocks that have caught my attention recently: $VRTX (Vertex Pharmaceuticals Incorporated) (Vertex Pharmaceuticals) and $NOW (ServiceNow Inc) 🔬 $VRTX - Vertex Pharmaceuticals: A leader in cystic fibrosis treatment, particularly... Show More
David Starlyte
$CRSP (CRISPR Therapeutics AG) - What is CRISPR? CRISPR Therapeutics has the most advanced pipeline among CRISPR-focused biotech stocks. The company and its partner, Vertex Pharmaceuticals ($VRTX (Vertex Pharmaceuticals Incorporated)), are developing treatments for genetic blood disorders beta-thalassemia... Show More
Like CommentShare
null
.
MarketUpdates
Edited
$VRTX (Vertex Pharmaceuticals Incorporated) Q3 2023 earnings report is expected to be released
26
OCT
REPORTS
Vertex Pharmaceuticals Incorporated Q3 2023 earnings report is expected to be released after market open
Notify me
VRTX
VRTX
Vertex Pharmaceuticals Incorporated
349.53
-4.75
(-1.34%)
Trade
Cristian Nicolescu
Edited
𝙏𝙞𝙢𝙚 𝙩𝙤 𝘿𝙤𝙨𝙚 𝘿𝙤𝙬𝙣 𝙤𝙣 $𝙑𝙍𝙏𝙓?💊 Hey, savvy investors! Taking a break from the automotive lane, let's switch gears and talk about a pharmaceutical frontrunner: Vertex Pharmaceuticals ($VRTX (Vertex Pharmaceuticals Incorporated)). Time to pop the lid and see if this pill is worth... Show More
Like CommentShare
Show more comments2 of 5
1 reply
1 reply
null
.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. The firm was founded in 1989, and its primary focus is on the researching and marketing of biotechnology solutions for the treatment of cystic fibrosis. The company has a number of approved therapies available that are aimed at the treatment of the underlying cause of cystic fibrosis. The company also operates advanced independent research and development programs in other areas, and has a number of investigational small molecule medicines in their pipeline, aimed at treating kidney diseases, pain, and genetic diseases such as sickle cell disease, Duchenne muscular dystrophy and Type 1 diabetes. Vertex Pharmaceuticals works in collaboration with Cystic Fibrosis Foundation Therapeutics Incorporated, CRISPR Therapeutics AG, and other organisations, and markets its products mainly to specialty healthcare providers in North America, as well as global government-owned providers. The firm has regularly been ranked as one of the industry's best places to work, including making Science Magazine's Top Employers list for 11 consecutive years, and being named a top place to work for LGBTQ equality by the Human Rights Campaign. The firm trades on the NASDAQ under the ticker VRTX. Learn more about the share price performance of VRTX on eToro.
Reshma Kewalramani, MD
CEO
4.8K
Employees
1989
Founded
Boston, Massachusetts, US
HQ
Show More

Upcoming Events

26
OCT
REPORTS
Vertex Pharmaceuticals Incorporated Q3 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Strong Buy
Price Target
385.25

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
65
Very High
Industry 
Avg. 47 
55
Environment
63
Social
72
Governance

People Also Bought